Literature DB >> 18221186

Intraocular delivery of anti-infective drugs-bacterial, viral, fungal and parasitic.

Ahmed Sallam1, Subash Jayakumar, Susan Lightman.   

Abstract

This article reviews the current literature about the use of intraocular drugs for treatment of bacterial, fungal, viral and protozoal intraocular infection. This route of administration has the advantage of delivering antimicrobials directly into the eye achieving a high therapeutic concentration above the MIC(90) of most pathogens and with minimal systemic side effects. It is usually well tolerated but carries a small risk of intraocular complications. Intraocular therapy is now the main therapeutic approach for treatment of bacterial endophthalmitis and has an important adjunctive role in the management of endogenous fungal endophthalmitis and viral retinitis. Intravitreal clindamycin therapy offers a recent additional strategy to treat ocular toxoplasmosis in patients who are intolerant or resistant to systemic treatment. Current researches is now focusing on new patents as well as on the use of intraocular lenses that incorporate antibiotics during cataract surgery and thus provide a sustained high antibiotic levels in the eye in the immediate postoperative period, not depending on patient's compliance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18221186     DOI: 10.2174/157489108783413164

Source DB:  PubMed          Journal:  Recent Pat Antiinfect Drug Discov        ISSN: 1574-891X


  2 in total

1.  International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics.

Authors:  Hermann A M Mucke; Peter Mucke; Eva Mucke
Journal:  Clin Ophthalmol       Date:  2009-06-02

2.  Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis.

Authors:  Lana Tamaddon; S Abolfazl Mostafavi; Reza Karkhane; Mohammad Riazi-Esfahani; Farid Abedin Dorkoosh; Morteza Rafiee-Tehrani
Journal:  Adv Biomed Res       Date:  2015-01-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.